Publication / Source: Originally published on Oncology Central (www.oncology-central.com) Authors: Sebastian Dennis-Beron
New research from The Saban Research Institute of Children’s Hospital Los Angeles (CHLA) (CA, US), has resulted in the development and testing of a novel biomarker assay that detects the presence of neuroblastoma as well as quantifying disease, even in cases where standard evaluations yield negative results.
Restricted Content / Members Only
You cannot view this content because It is available to members only. Please Login or Register to view this area.